Esperion Therapeutics, Inc. (ESPR)
NASDAQ: ESPR · Real-Time Price · USD
1.500
-0.110 (-6.83%)
At close: Mar 28, 2025, 4:00 PM
1.501
+0.001 (0.05%)
After-hours: Mar 28, 2025, 7:59 PM EDT
Esperion Therapeutics Stock Forecast
Stock Price Forecast
The 7 analysts with 12-month price forecasts for Esperion Therapeutics stock have an average target of 6.36, with a low estimate of 2.50 and a high estimate of 16. The average target predicts an increase of 324.00% from the current stock price of 1.50.
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for Esperion Therapeutics stock from 7 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Oct '24 | Nov '24 | Dec '24 | Jan '25 | Feb '25 | Mar '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 2 | 2 | 2 | 2 |
| Buy | 0 | 0 | 1 | 2 | 2 | 3 |
| Hold | 1 | 0 | 1 | 1 | 1 | 1 |
| Sell | 1 | 1 | 1 | 1 | 1 | 1 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 4 | 3 | 5 | 6 | 6 | 7 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $16 | Strong Buy | Reiterates | $16 | +966.67% | Mar 20, 2025 |
| Citizens Capital Markets | Citizens Capital Markets | Buy Reiterates $4 | Buy | Reiterates | $4 | +166.67% | Mar 5, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $16 | Strong Buy | Reiterates | $16 | +966.67% | Mar 4, 2025 |
| JMP Securities | JMP Securities | Buy Reiterates $7 → $4 | Buy | Reiterates | $7 → $4 | +166.67% | Feb 11, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $16 | Strong Buy | Reiterates | $16 | +966.67% | Feb 11, 2025 |
Financial Forecast
Revenue This Year
350.62M
from 332.31M
Increased by 5.51%
Revenue Next Year
355.59M
from 350.62M
Increased by 1.42%
EPS This Year
-0.05
from -0.28
EPS Next Year
-0.22
from -0.05
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 420.5M | 451.5M | 636.9M | ||
| Avg | 350.6M | 355.6M | 531.4M | ||
| Low | 245.1M | 204.9M | 426.6M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 26.5% | 28.8% | 79.1% | ||
| Avg | 5.5% | 1.4% | 49.4% | ||
| Low | -26.2% | -41.6% | 20.0% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | 0.42 | -0.02 | 0.08 |
| Avg | -0.05 | -0.22 | 0.07 |
| Low | -0.43 | -0.52 | 0.05 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | - | - | - |
| Avg | - | - | - |
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.